Tango Therapeutics, Inc. (TNGX) Tops Q3 EPS by 11c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.23), $0.11 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $10.73 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
• Barclays says AI trade is maturing, favors greater diversification